US20120288889A1 - Reagent for blood cell counting and blood analysis method - Google Patents
Reagent for blood cell counting and blood analysis method Download PDFInfo
- Publication number
- US20120288889A1 US20120288889A1 US13/467,840 US201213467840A US2012288889A1 US 20120288889 A1 US20120288889 A1 US 20120288889A1 US 201213467840 A US201213467840 A US 201213467840A US 2012288889 A1 US2012288889 A1 US 2012288889A1
- Authority
- US
- United States
- Prior art keywords
- reagent
- blood
- cell counting
- blood cell
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 121
- 238000004820 blood count Methods 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000004159 blood analysis Methods 0.000 title claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 120
- 239000008280 blood Substances 0.000 claims abstract description 120
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 92
- 239000002245 particle Substances 0.000 claims abstract description 58
- 210000000601 blood cell Anatomy 0.000 claims abstract description 34
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical class ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims abstract description 18
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- 239000012895 dilution Substances 0.000 claims description 34
- 238000010790 dilution Methods 0.000 claims description 34
- 239000012528 membrane Substances 0.000 claims description 17
- 230000003204 osmotic effect Effects 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 238000007865 diluting Methods 0.000 claims description 10
- 239000003792 electrolyte Substances 0.000 claims description 10
- 230000002744 anti-aggregatory effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000002949 hemolytic effect Effects 0.000 claims description 9
- 238000009826 distribution Methods 0.000 claims description 7
- 239000003945 anionic surfactant Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 description 37
- -1 chloroquine salt Chemical class 0.000 description 19
- 239000000758 substrate Substances 0.000 description 19
- 239000011347 resin Substances 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 150000003242 quaternary ammonium salts Chemical group 0.000 description 8
- 239000002736 nonionic surfactant Substances 0.000 description 7
- 210000000352 storage cell Anatomy 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 229960003677 chloroquine Drugs 0.000 description 4
- 210000000624 ear auricle Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical class C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- QKICWELGRMTQCR-UHFFFAOYSA-N 4-[(7-chloroquinolin-4-yl)azaniumyl]pentyl-diethylazanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 QKICWELGRMTQCR-UHFFFAOYSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- MGJKQDOBUOMPEZ-UHFFFAOYSA-N N,N'-dimethylurea Chemical compound CNC(=O)NC MGJKQDOBUOMPEZ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- VICYBMUVWHJEFT-UHFFFAOYSA-N dodecyltrimethylammonium ion Chemical compound CCCCCCCCCCCC[N+](C)(C)C VICYBMUVWHJEFT-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WSZKUEZEYFNPID-UHFFFAOYSA-N hydrogen sulfate;quinolin-1-ium Chemical compound OS(O)(=O)=O.N1=CC=CC2=CC=CC=C21 WSZKUEZEYFNPID-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- XNRNJIIJLOFJEK-UHFFFAOYSA-N sodium;1-oxidopyridine-2-thione Chemical compound [Na+].[O-]N1C=CC=CC1=S XNRNJIIJLOFJEK-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JZBRFIUYUGTUGG-UHFFFAOYSA-J tetrapotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JZBRFIUYUGTUGG-UHFFFAOYSA-J 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/1031—Investigating individual particles by measuring electrical or magnetic effects
- G01N15/12—Investigating individual particles by measuring electrical or magnetic effects by observing changes in resistance or impedance across apertures when traversed by individual particles, e.g. by using the Coulter principle
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
Definitions
- the present invention relates to a reagent for blood cell counting, which is mixed with capillary blood collected from a living body, and to a blood analysis method of counting blood cells in capillary blood collected from a living body using a particle analyzer.
- a particle analyzer which uses an analysis method called “flow cytometry” is used as a means for counting blood cells in blood.
- collected blood is diluted with a hemolytic reagent to prepare a blood sample, and the blood sample is introduced into a particle analyzer, in which particles having a specific volume range (e.g., about 25 to 450 fL) are then counted one by one.
- the hemolytic reagent contains a component that breaks the membrane of blood cells. Because erythrocytes have no nucleus, when the membrane of the erythrocytes is broken, hemoglobin is released and the erythrocytes lose their shape or size, and thus are lysed.
- leukocytes have a nucleus
- these cells are lysed to leave bare nuclei (particles) which are then dispersed in the blood sample. Accordingly, leukocytes can be counted by introducing a blood sample containing lysed erythrocytes into a particle analyzer and counting particles having a specific volume range in the particle analyzer.
- Methods of collecting blood from a living body in blood testing include two methods: a method of collecting venous blood from a subcutaneous vein; and a method of collecting capillary blood from a fingertip or an earlobe.
- leukocyte volume histogram of FIG. 11 the noise derived from the debris of lysed platelets or erythrocytes (ghost “G”) and the peak derived from leukocytes (leukocyte “W”) are clearly distinguished from each other.
- G debris of lysed platelets or erythrocytes
- W peak derived from leukocytes
- venous blood is diluted with a hemolytic reagent containing ethylenediamine tetraacetate as an anti-aggregation agent (platelet anti-aggregation agent), and thus a means for inhibiting the aggregation of platelets in a blood sample is established (see, for example, Patent Document 1).
- the tailing portion T of the ghost peak G and the leading portion R of the leukocyte peak W overlap with each other over a relatively wide range. For this reason, leukocytes cannot be counted with high accuracy. This is because platelet aggregates are miscounted over the range from the tailing portion T of the ghost peak G to the leading portion R of the leukocyte peak W.
- Collection of capillary blood is performed by pricking a fingertip or an earlobe with a lancet to obtain a very small amount of blood and is advantageous in that blood can be collected in a simple and rapid manner.
- a tissue solution is likely to be incorporated into the blood being collected, and thus platelets may aggregate rapidly after collection.
- Ethylenediamine tetraacetate has the function of inhibiting the aggregation of platelets, but does not have the function of dissociating platelet aggregates. Thus, even when capillary blood in which platelets aggregate rapidly after blood collection is treated with a hemolytic reagent containing ethylenediamine tetraacetate, platelet aggregates cannot be dissociated.
- the present invention has been made in order to solve the above technical problem, and it is an object of the present invention to provide a novel reagent for blood cell counting and a blood analysis method, which enable blood cells such as leukocytes to be counted with high accuracy by dissociating platelet aggregates in capillary blood collected from a living body.
- the reagent for blood cell counting according to the present invention is used to dilute capillary blood collected from a living body to prepare a blood sample in order to count blood cells in the collected capillary blood using a particle analyzer, and is characterized in that it is an aqueous solution containing a chloroquine salt.
- the reagent for blood cell counting is used to dilute “capillary blood” collected from a living body to prepare a blood sample in order to count blood cells such as leukocytes in the collected capillary blood using a “particle analyzer”.
- capillary blood means blood obtained by pricking a fingertip or an earlobe with a lancet (fingertip blood or earlobe blood).
- particle analyzer means a particle analyzer (flow cytometer or coulter counter) that uses an analysis method called flow cytometry in which fine particles are dispersed in a fluid which is then allowed to flow thinly while individual particles in the fluid are counted.
- the particle analyzer may be broadly divided into two types: one that uses an optical detection method in which light scattering or fluorescence is detected; and the other that uses an electrical resistance detection method in which a change in impedance when particles pass through a thin hole is detected.
- the electrical resistance detection method is superior in that it is simple and convenient.
- chloroquine salt that is contained in the reagent for blood cell counting according to the present invention serves to dissociate platelet aggregates in capillary blood and refers to a compound having a quinoline backbone and containing a chloro group.
- salts of chloroquinoline derivatives which have a chloro group introduced at position 7 of the quinoline backbone and an amino group introduced at position 4 of the quinoline backbone are preferably used in the present invention.
- chloroquine salt examples include chloroquine diphosphate (7-chloro-4-[4-(diethylamino)-1-methylbutylamino]quinoline diphosphate), hydroxychloroquine sulfate (7-chloro-4-[4-N-ethyl-N-(2-hydroxyethyl)amino]-1-methylbutylamino)quinoline sulfate), and the like.
- the reagent for blood cell counting according to the present invention preferably contains 10 g/L or more of the chloroquine salt.
- a dilution process of diluting blood collected from a living body about 100-500-fold with a reagent is carried out. It has been found that when a very small amount of a chloroquine salt is contained in a reagent, platelet aggregates can be dissociated by carrying out the dilution process using the reagent. With respect to the dissociation of platelet aggregates, the upper limit of the concentration of the chloroquine salt in the reagent is not specifically limited. However, as the concentration of the chloroquine salt increases, the cost of the reagent increases. For this reason, the upper limit of the concentration of the chloroquine salt is preferably limited to 100 g/L.
- the reagent for blood cell counting according to the present invention preferably further contains a surfactant having hemolytic activity.
- a surfactant any surfactant may be used without particular limitation, so long as it breaks the membrane of blood cells when mixed with blood, and lyses erythrocytes in blood while lysing leukocytes to leave bare nuclei.
- the surfactant may be ionic or nonionic.
- the ionic surfactant is preferably an anionic surfactant.
- the anionic surfactant is preferably a quaternary ammonium salt. Specific examples of the quaternary ammonium salt include chlorides or bromides of hexadecyltrimethyl ammonium or dodecyltrimethyl ammonium. Meanwhile, specific examples of the nonionic surfactant include saponin.
- the reagent for blood cell counting according to the present invention contains a chloroquine salt such that it can dissociate platelet aggregates.
- concentration of a surfactant in the reagent for blood cell counting is limited such that a leukocyte peak in a leukocyte volume histogram will be clear.
- the reagent for blood cell counting according to the present invention preferably contains 10-50 g/L of the surfactant.
- the reagent for blood cell counting contains 10 g/L or more of the surfactant, it can break the membrane of blood cells when the dilution process is carried out using the reagent, and it can lyse erythrocytes in blood in the dilution step while lysing leukocytes to leave bare nuclei.
- the concentration of the surfactant in the reagent for blood cell counting is more than 50 g/L, the volume of leukocytes in the blood sample will decrease.
- the concentration of the surfactant in the reagent for blood cell counting according to the present invention is preferably set in the range of 10 to 50 g/L (more preferably 20 to 40 g/L).
- the reagent for blood cell counting according to the present invention preferably further contains an “electrolyte” such that the osmotic pressure of the reagent is adjusted to 200-600 Osm/kg.
- electrolyte is not specifically limited, so long as it is ionized to cations, such as sodium ions, potassium ions or magnesium ions, and anions such as chloride ions, bromide ions or phosphate ions, when it is dissolved in water.
- cations such as sodium ions, potassium ions or magnesium ions
- anions such as chloride ions, bromide ions or phosphate ions, when it is dissolved in water.
- Specific examples of the electrolyte include sodium chloride, sodium bromide, potassium chloride, potassium bromide, calcium chloride, calcium bromide, magnesium chloride, magnesium bromide, sodium phosphate, potassium phosphate, and the like.
- the concentration of the electrolyte in the reagent for blood cell counting is so low that the osmotic pressure of the reagent is less than 200 Osm/kg, the expansion and degradation of leukocytes will result.
- the concentration of the electrolyte in the reagent for blood cell counting is so excessively high that the osmotic pressure of the reagent is more than 600 Osm/kg, the volume of leukocytes will decrease such that the leukocyte peak will shift to the lower volume side so as to approach the ghost peak.
- the osmotic pressure of the reagent for blood cell counting is preferably adjusted in the range of 200 to 600 Osm/kg (more preferably, 300 to 400 Osm/kg).
- the leukocyte peak can be prevented from being excessively close to the ghost peak.
- the reagent for blood cell counting according to the present invention is configured such that a minimum value of a relative frequency of valleys in distribution where the tailing portion of a ghost peak and the leading portion of a leukocyte peak in a leukocyte volume histogram, which is obtained when introducing the blood sample into the particle analyzer, overlap with each other lies within a particle volume range of 35 to 50 fL.
- the reagent for blood cell counting according to the present invention preferably further contains an “anti-aggregation agent”.
- the term “anti-aggregation agent” means one having the property of inhibiting the aggregation of platelets.
- platelets including platelets dissociated by the chloroquine salt
- the anti-aggregation agent include salts of ethylenediamine tetraacetate (EDTA), for example, EDTA-2Na (disodium salt), EDTA-2K (dipotassium salt), EDTA-3Na (trisodium salt) or EDTA-3K (tripotassium salt), heparin, acetylsalicylic acid, magnesium sulfate, etc.
- concentration of the anti-aggregation agent in the reagent for blood cell counting is preferably 0.01-0.2 g/L, but is not specifically limited thereto.
- the reagent for blood cell counting according to the present invention is preferably diluted with a buffer solution in order to stabilize the pH (hydrogen ion concentration) of the reagent.
- the reagent for blood cell counting according to the present invention may further contain a nonionic surfactant for adjusting surface tension, a pH-adjusting agent for adjusting pH, a membrane protective agent for stabilizing bare nuclei remaining after lysis of leukocytes, a preservative for increasing storage stability, and other various additives.
- buffer solution examples include acetate buffer, phosphate buffer, citrate buffer, borate buffer, tartrate buffer, and tris buffer.
- pH-adjusting agent examples include sodium hydroxide and hydrochloric acid.
- nonionic surfactant for adjusting surface tension is not specifically limited, so long as it contains a hydrophilic group and a hydrophobic group in the molecule and has the property of lowering the surface tension of the reagent for blood cell counting.
- specific examples of the nonionic surfactant include “ether-type nonionic surfactants”, such as polyoxyethylene decyl ether, polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene octylphenyl ether or polyoxyethylene nonylphenyl ether; and ester-type nonionic surfactants (including etherester-type nonionic surfactants), such as polyoxyethylene lauric acid ester, polyoxyethylene oleic acid ester, polyoxyethylene sorbitan lauric acid ester, polyoxyethylene sorbitan oleic acid ester, sorbitan mono- (or di-) oleic acid ester, sorbitan mono- (or di-) lauric acid ester
- the “preservative” include sodium azide, sodium omadine, Kathon CG, ROCIMA® 553, thimerosal and the like.
- the “membrane protective agent” include lower alcohols such as isopropyl alcohol, glutaraldehyde, dimethyl urea, glucose and the like.
- the blood analysis method of the present invention is a blood analysis method in which blood cells such as leukocytes, which are contained in capillary blood collected from a living body, are counted in a particle analyzer, the blood analysis method comprising the steps of: collecting capillary blood from a living body; diluting the collected capillary blood with the reagent for blood cell counting according to the present invention to prepare a blood sample; and introducing the blood sample into the particle analyzer and counting leukocytes in the blood sample using the particle analyzer.
- the step of counting the leukocytes comprises determining a count start volume in a particle volume range of 35 to 50 fL and counting particles having a volume equal to or larger than the determined count start volume as leukocytes.
- Counting of leukocytes in the particle analyzer is performed by considering particles having a specific range of volume in the blood sample as leukocytes, and counting the particles one by one. That is, the “count start volume” as used herein means the lower limit of the specific range of volume.
- the upper limit of the specific range in counting of leukocytes in the particle analyzer is the simple end point of the counting and is not a particularly important factor. In general, the upper limit of the specific range in the counting is about 300-500 fL.
- platelet aggregates in capillary blood collected from a living body can be dissociated, and thus blood cells such as leukocytes can be counted with high accuracy using a particle analyzer.
- FIG. 1 is a top view showing a measurement unit in a micro blood cell counter.
- FIG. 2 is a side view showing a measurement unit in a micro blood cell counter.
- FIG. 3( a ) is a sectional view showing a dilution bottle in a micro blood cell counter
- FIG. 3( b ) is a bottom view of the dilution bottle
- FIG. 3( c ) is a sectional view showing a state in which a dilution bottle according to another embodiment is set with a bottle guide into a blood counter
- FIG. 3( d ) is a partial sectional view showing another embodiment of the dilution bottle shown in FIG. 3( c )
- FIG. 3( e ) is a partial sectional view showing still another embodiment of the dilution bottle shown in FIG. 3( c ).
- FIG. 4 is a top view showing a body in a micro blood cell counter.
- FIG. 5 is a side view showing a body in a micro blood cell counter.
- FIG. 6 is a perspective view showing a measurement unit (provided with a dilution bottle) inserted into a body in a micro blood cell counter.
- FIGS. 7( a ) and 7 ( b ) are leukocyte volume histograms obtained by measuring blood samples diluted with the inventive reagents for blood cell counting according to Examples 1 and 2 , respectively; and FIG. 7( c ) is a leukocyte volume histogram obtained by measuring a blood sample diluted with a reagent for blood cell counting according to Comparative Example 1.
- FIGS. 8( a ), 8 ( b ), 8 ( c ) and 8 ( d ) are leukocyte volume histograms obtained by measuring blood samples diluted with the inventive reagents for blood cell counting according to Examples 3, 1, 4 and 5, respectively.
- FIGS. 9( a ), 9 ( b ) and 9 ( c ) are leukocyte volume histograms obtained by measuring blood samples diluted with the inventive reagents for cell blood counting according to Examples 6, 1 and 7, respectively; and FIGS. 9( d ) and 9 ( e ) are leukocyte volume histograms obtained by measuring blood samples diluted with reagents for blood cell counting according to Comparative Examples 2 and 3, respectively.
- FIGS. 10( a ), 10 ( b ) and 10 ( c ) are leukocyte volume histograms obtained by measuring blood samples diluted with the inventive reagents for blood cell counting according to Examples 8, 1 and 9, respectively; and FIGS. 10( d ) and 10 ( e ) are leukocyte volume histograms obtained by measuring blood cells diluted with reagents for blood cell counting according to Comparative Examples 4 and 5, respectively.
- FIG. 11 is a leukocyte volume histogram obtained by measuring a blood sample prepared by diluting venous blood with a reagent for blood cell counting according to the prior art.
- FIG. 12 is a leukocyte volume histogram obtained by measuring a blood sample prepared by diluting capillary blood with a reagent for blood cell counting according to the prior art.
- a particle analyzer used in this embodiment was a micro blood cell counter (trade name (tentative name): Palm-LC; manufactured by Horiba Manufacturing Co., Ltd.).
- FIGS. 1 and 2 show a measurement unit 1 in a micro blood cell counter.
- the measurement unit 1 is prepared in the form of a cartridge made of a resin such as polymethylmethacrylate (PMMA).
- a resin substrate 2 of the measurement unit 1 comprises: a fluid path 3 for connection to the outside, one end of which is connected to a pump connection port 17 ; a liquid storage cell 7 connected to the other end of the fluid path 3 and having fluid paths defined by walls 4 , 5 and 6 ; an absorbance-measuring cell 9 connected to the liquid storage cell 7 through a fluid path 8 ; a detection fluid path 11 connected to the absorbance-measuring cell 9 through a fluid path 10 ; a capillary 13 connected to the detection fluid path 11 through a fluid path 12 having an approximately S-shape; and a sensor mounting portion 16 provided between the fluid path 10 and the fluid path 12 .
- PMMA polymethylmethacrylate
- the resin substrate 2 includes a resin substrate 2 a and a resin substrate 2 b .
- the liquid storage cell 7 is formed with a depth of, for example, about 4 mm, and the absorbance-measuring cell 9 is also formed with a predetermined depth.
- the fluid path 3 for connection to the outside, the fluid paths 8 , 10 and 12 , the detection fluid path 11 and a capillary-receiving fluid path 18 are formed with a width and depth of, for example, about 1 mm and about 1 mm, respectively.
- the sensor mounting portion 16 is formed on the resin substrate 2 b .
- the allocation of the fluid paths and other elements formed on the resin substrates 2 a and 2 b is not limited to the above, and the depth, width and the length of these elements may be allocated such that the resin substrates 2 a and 2 b can be effectively used.
- the resin substrate 2 a and the resin substrate 2 b are bonded to each other by means of, for example, an adhesive or a double-sided adhesive tape, so as to prevent liquid leakage.
- the capillary 13 made of, for example, glass, is buried in the capillary-receiving fluid path 18 , and is fixed to the capillary receiving fluid path 18 by, for example, an adhesive, while the outer circumferential surface of the capillary 13 and the inner circumferential surface of the capillary-receiving fluid path are sealed.
- a bottle guide 19 is aligned with the center of the capillary 13 .
- the bottle guide 19 is bonded to the end sides of the resin substrates 2 a and 2 b .
- the pump connection port 17 is connected to the fluid path 3 for connection to the outside 3 , and in this state, the pump connection port 17 is bonded to the end sides of the resin substrates 2 a and 2 b .
- a sensor chip 145 is provided with electrodes 14 and 15 for detecting variation in the impedance of a blood sample.
- a sensor substrate 20 having the sensor chip 145 mounted thereon is attached to a sensor mounting portion 16 to provide a sensor unit, thereby completing the measurement unit 1 in this micro blood cell counter.
- the electrodes 14 and 15 are connected to lead lines 21 and 22 , respectively, as the sensor chip 145 is mounted on the sensor substrate 20 , whereby a signal in the sensor unit can be drawn from the lead lines 21 and 22 .
- the sensor chip 145 is attached to the sensor mounting portion 16 in a later step.
- the sensor chip 145 may be formed on the resin substrate 2 a or 2 b , before the electrodes 14 and 15 are attached to the sensor chip 145 by sputtering.
- FIGS. 3( a ) and 3 ( b ) show a dilution bottle 23 .
- the dilution bottle 23 comprises: a container 24 for receiving a reagent “S” for blood cell counting; an air hole 27 formed through the top of the container 24 ; a seal 26 for sealing the air hole 27 ; and a membrane 25 attached to the bottom of the container 24 .
- the dilution bottle 23 receives the reagent “S” for blood cell counting in the container 24 and is sealed by the seal 26 and the membrane 25 .
- the dilution bottle 23 is not limited to the one shown in FIGS. 3( a ) and 3 ( b ). For example, in the dilution bottle 23 shown in FIG.
- the lower portion of the container 24 has a reduced diameter
- a guide portion 28 is provided such that it extends downward from the membrane 25
- the container 24 , the membrane and the guide portion 28 are formed integrally with each other.
- This dilution bottle 23 is configured such that, when the container 24 is allowed to slide along the bottle guide 19 , the guide portion 28 comes into close contact with the outer circumferential side of the capillary 13 such that it can guide the corresponding capillary 13 to the membrane 25 .
- an atmosphere opening portion 261 consisting of, for example, a resin check valve, is provided in the central portion of the seal 26 , and when or before the capillary 13 is inserted into and passed through the membrane 25 , a ventilation needle (not shown) is inserted into and passed through the atmosphere opening portion 261 such that the inside of the container is ventilated.
- FIG. 3( c ) shows that the container 24 , the membrane 25 and the guide portion 28 are formed integrally with each other.
- the dilution bottle 23 may also be constructed by attaching the membrane 25 to the inlet at the bottom of the container 24 and fitting a separate guide member 281 therewith.
- the dilution bottle 23 may also be constructed such that the reagent “S” for blood cell counting is received in the container 24 by pressing a sphere 29 into the position corresponding to the membrane 25 and such that the sphere 29 is pressed into the container 24 by the capillary 13 in the measurement process so as to open the container 24 .
- the capacity of the container 24 is not specifically limited, because it varies depending on the type of micro blood cell counter or the dilution factor of the reagent “S” for blood cell counting.
- the capacity of the container 24 may preferably be 0.1-2 ml, more preferably 0.3-1.0 ml, and even more preferably 0.5 ml.
- FIGS. 4 and 5 show a body 100 of the micro blood cell counter.
- the body 100 of the micro blood cell counter is covered with a case 51 , and three-way electronic valves 53 and 54 , a diaphragm pump 55 , batteries 56 , 57 , 58 and 59 , a liquid crystal display (LCD) 61 , a circuit board 62 and a cartridge setting portion 63 are provided in the case 51 .
- a transparent plate 60 is attached in a window frame formed on the top surface of the case 51 such that the display of the LCD 61 can be seen from the outside.
- a battery cover 65 which is open or closed in order to set or replace the batteries 56 , 57 , 58 and 59 is provided over the side and bottom of the case 51 .
- the discharge (pressure) side of the diaphragm pump 55 is connected to the common port of the three-way electronic valve 53 , and the suction (vacuum) side of the diaphragm pump 55 is connected to the common port of the three-way electronic value 54 .
- the NO port (normally open port) of the three-way electronic valve 53 is connected to the NC port (normally closed port) of the three-way valve 54
- the NC port of the three-way electronic valve 53 is connected to the NO port of the three-way electronic valve 54 .
- the line that connects the NO port of the three-way electronic valve 53 with the NC port of the three-way electronic valve 54 is configured such that the pump connection port 17 of the cartridge-type measurement unit 1 is connected thereto when the measurement unit 1 prepared in the form of the cartridge is set in the cartridge-setting portion 63 .
- Operating power is supplied to the three-way electronic valves 53 and 54 , the diaphragm pump 55 and the LCD 61 by the batteries 56 , 57 , 58 and 59 , and the three-way electronic valves 53 and 54 , the diaphragm pump 55 and the LCD 61 are controlled by a control circuit provide on the circuit board 62 .
- a signal indicating the variation in impedance is supplied to an operational circuit provided on the circuit board 62 , whereby blood cells in the blood sample are measured, and the results of the measurement are displayed in the LCD 61 .
- a step of collecting capillary blood from a living body is first carried out.
- the blood collecting step is carried out by pricking, for example, the fingertip of a subject (living body) with the tip of the capillary and drawing capillary blood (1 ⁇ L) into the capillary 13 by a capillary phenomenon.
- a step of diluting the collected capillary blood with the reagent “S” for blood cell counting of the present invention is carried out to prepare a blood sample.
- the dilution bottle 23 containing the reagent “S” for blood cell counting is allowed to slide along the bottle guide 19 , and the membrane 25 of the dilution bottle 23 is broken at the tip of the capillary 13 , whereby the tip of the capillary 13 is inserted into the dilution bottle 23 .
- the seal 26 of the dilution bottle 23 is removed.
- the dilution bottle 23 is open to the atmosphere through the hole at the top thereof.
- the pump connection port 17 is connected to the diaphragm pump 55 accommodated in the body 100 of the micro blood cell counter. Also, the sensor substrate 20 is electrically connected to an impedance measurement circuit provided in the body 100 .
- the diaphragm pump 55 when the diaphragm pump 55 is operated to apply pressure to the inside of the capillary 13 through the pump connection portion 17 , the fluid path 3 for connection to the outside, the liquid storage cell 7 , the fluid path 8 , the absorbance-measuring cell 9 , the fluid path 10 , the detection fluid path 11 and the fluid path 12 , the capillary blood in the capillary 13 is then pressure-introduced into the dilution bottle 23 . At this time, bubbling occurs in the dilution bottle 23 , so that the capillary blood and the reagent “S” for blood cell counting are mixed, thereby obtaining a blood sample diluted with the reagent “S” for blood cell counting (dilution factor: 251).
- a step of counting leukocytes in the blood sample is carried out according to the present invention.
- the diaphragm pump 55 is operated to apply a vacuum to the inside of the capillary 13 through the pump connection port 17 , the fluid path 3 for connection to the outside, the liquid storage cell 7 , the fluid path 8 , the absorbance-measuring cell 9 , the fluid path 10 , the detection fluid path 11 and the fluid path 12 .
- the blood sample in the dilution bottle 23 is introduced into the detection fluid path 11 through the capillary 13 and the fluid path 12 .
- the variation in impedance between the electrodes 14 and 15 provided in the detection fluid path 11 occurs, and the micro blood cell counter measures particles in the blood sample on the basis of this variation in impedance.
- the diluted blood passed through the detection fluid path 11 flows to the absorbance-measuring cell 9 through the fluid path 10 .
- the amount of hemoglobin in the blood sample can be measured by measuring the absorbance of the absorbance-measuring cell 9 with an optical sensor (not shown).
- the blood sample passed through the absorbance-measuring cell 9 flows to the liquid storage cell 7 through the fluid path 8 and is collected as waste.
- the measurement unit 1 is separated from the body of the micro blood cell unit and wasted together with the blood sample collected in the liquid storage cell 7 .
- a reagent for blood cell counting according to the present invention which had an osmotic pressure of 390 Osm/kg, was prepared in the same manner as Example 1, except that dodecyltrimethyl ammonium chloride (36.6 g/L) was used as the quaternary ammonium.
- a reagent for blood cell counting having an osmotic pressure of 390 Osm/kg was prepared in the same manner as Example 1, except that the chloroquine salt was not used.
- the inventive reagents for blood cell counting according to Examples 1 and 2 and the reagent for blood cell counting according to Comparative Example 1 were placed and sealed in different dilution bottles 23 . Then, the fingertip of a subject was pricked with the top of the capillary 13 provided in the measurement unit 1 to draw capillary blood into the capillary 13 , and the top of the capillary 13 was inserted into the dilution bottle 23 . Then, the measurement unit 1 was inserted into the cartridge-setting portion 63 of the micro blood cell counter, thereby performing the blood analysis method of the present invention.
- FIGS. 7( a )- 7 ( c ) show the leukocyte volume histograms obtained by this analysis method.
- the leukocyte volume histograms shown in FIGS. 7( a ) and 7 ( b ) were those obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Examples 1 and 2, respectively.
- the ghost noise “G” and the leukocyte peak “W” were clearly isolated from each other and that platelet aggregates had little or no influence on miscounting.
- a minimum value of a relative frequency of valleys in distribution where the tailing portion of the ghost peak and the leading portion of the leukocyte peak in the histogram overlap with each other lies within a particle volume range of 35 to 50 fL.
- leukocytes in the blood samples can be counted with high accuracy by determining a count start volume within a particle volume range of 35 to 50 fL and counting particles having a volume equal to or larger than the determined count start volume as leukocytes.
- FIG. 7( c ) shows a leukocyte volume histogram obtained by measuring the blood sample diluted with the reagent for blood cell counting according to Comparative Example 1.
- the ghost peak was significantly larger, and the tailing portion thereof was shifted toward the higher volume side and overlapped with the leading portion of the leukocyte peak over a wide range.
- the count start volume is determined within a particle volume range of 35 to 50 fL, miscounting derived from platelet aggregates occurs, resulting in that leukocytes cannot be counted with high accuracy.
- Reagents for blood cell counting were prepared in the same manner as Example 1, except that the concentration of the chloroquine salt was changed to 10 g/L (Example 3), 40 g/L (Example 4) and 80 g/L (Example 5).
- FIGS. 8( a )- 8 ( d ) shows the obtained leukocyte volume histograms.
- FIGS. 8( a ), 8 ( b ), 8 ( c ) and 8 ( d ) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Examples 3, 1, 4 and 5, respectively.
- Reagents for blood cell counting were prepared in the same manner as Example 1, except that the concentration of the quaternary ammonium salt was changed to 10 g/L (Example 6) and 50 g/L (Example 7).
- Reagents for blood cell counting were prepared in the same manner as Example 1, except that the concentration of the quaternary ammonium salt was changed to 5 g/L (Comparative Example 2) and 100 g/L (Comparative Example 3).
- FIGS. 9( a )- 9 ( e ) shows the obtained leukocyte volume histograms.
- FIGS. 9( a ), 9 ( b ) and 9 ( c ) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Examples 6, 1 and 7, respectively. Also, FIGS. 9( d ) and 9 ( e ) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Comparative Examples 2 and 3, respectively.
- a minimum value of a relative frequency of valleys in distribution where the tailing portion of the ghost peak and the leading portion of the leukocyte peak in the histogram overlap with each other can lie within a particle volume range of 35 to 50 fL.
- Reagents for blood cell counting according to the present invention were prepared in the same manner as Example 1, except that the osmotic pressures of the reagents were adjusted to 200 Osm/kg (Example 8) and 600 Osm/kg (Example 9) by changing the concentration of NaCl serving as the electrolyte.
- Reagents for blood cell counting were prepared in the same manner as Example 1, except that the osmotic pressures of the reagents were adjusted to 100 Osm/kg (Comparative Example 4) and 1000 Osm/kg (Comparative Example 9) by changing the concentration of NaCl serving as the electrolyte.
- FIGS. 10( a )- 10 ( e ) shows the obtained leukocyte volume histograms.
- FIGS. 10( a ), 10 ( b ) and 10 ( c ) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Examples 8, 1 and 9, respectively. Also, FIGS. 10( d ) and 10 ( e ) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Comparative Examples 4 and 5, respectively.
- a minimum value of a relative frequency of valleys in distribution where the tailing portion of the ghost peak and the leading portion of the leukocyte peak in the histogram overlap with each other can lie within a particle volume range of 35 to 50 fL.
- the present invention enables leukocytes in capillary blood to be counted with high accuracy.
- the present invention can also be used to analyze other blood components, such as platelets or erythrocytes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Ecology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Disclosed is a novel reagent for blood cell counting and a novel blood analysis method, which enable blood cells such as leukocytes to be counted with high accuracy by dissociating platelet aggregates in capillary blood collected from a living body. The reagent for blood cell counting is used to dilute capillary blood collected from a living body to prepare a blood sample in order to count blood cells in the collected capillary blood using a particle analyzer, and is an aqueous solution containing a chloroquine salt.
Description
- This application claims, under 35 USC 119(a), priority based on Japanese Patent Application No. 2011-105611, filed on May 10, 2011, the disclosure of which is incorporated herein by reference in its entirety.
- The present invention relates to a reagent for blood cell counting, which is mixed with capillary blood collected from a living body, and to a blood analysis method of counting blood cells in capillary blood collected from a living body using a particle analyzer.
- Conventionally, a particle analyzer which uses an analysis method called “flow cytometry” is used as a means for counting blood cells in blood.
- In the process of counting erythrocytes in blood, collected blood is diluted with physiological saline to prepare a blood sample, and the blood sample is introduced into a particle analyzer, in which particles having a specific volume range (e.g., 36-60 femtoliter (fL=10−15 liter)) are then counted one by one. At this time, leukocytes having a volume almost equal to that of erythrocytes are also counted, but the error caused by counting leukocytes is negligible because the concentration of leukocytes in blood is generally about 0.1-0.2% based on the concentration of erythrocytes.
- In contrast, in the process of counting leukocytes in blood, collected blood is diluted with a hemolytic reagent to prepare a blood sample, and the blood sample is introduced into a particle analyzer, in which particles having a specific volume range (e.g., about 25 to 450 fL) are then counted one by one. The hemolytic reagent contains a component that breaks the membrane of blood cells. Because erythrocytes have no nucleus, when the membrane of the erythrocytes is broken, hemoglobin is released and the erythrocytes lose their shape or size, and thus are lysed. On the other hand, because the leukocytes have a nucleus, these cells are lysed to leave bare nuclei (particles) which are then dispersed in the blood sample. Accordingly, leukocytes can be counted by introducing a blood sample containing lysed erythrocytes into a particle analyzer and counting particles having a specific volume range in the particle analyzer.
- Methods of collecting blood from a living body in blood testing include two methods: a method of collecting venous blood from a subcutaneous vein; and a method of collecting capillary blood from a fingertip or an earlobe.
- In the case in which a blood sample obtained by diluting venous blood with a hemolytic reagent is analyzed in a particle analyzer, as shown in the leukocyte volume histogram of
FIG. 11 , the noise derived from the debris of lysed platelets or erythrocytes (ghost “G”) and the peak derived from leukocytes (leukocyte “W”) are clearly distinguished from each other. Thus, leukocytes can be counted with relatively high accuracy. - Because collection of venous blood is performed by inserting a syringe needle into a subcutaneous vein and collecting blood directly from the blood vessel, the aggregation of platelets immediately after blood collection is not generally admitted. In addition, collected venous blood is diluted with a hemolytic reagent containing ethylenediamine tetraacetate as an anti-aggregation agent (platelet anti-aggregation agent), and thus a means for inhibiting the aggregation of platelets in a blood sample is established (see, for example, Patent Document 1).
-
- Patent Document 1: Japanese Unexamined Patent Publication No. Hei 3-144364
- However, in the case in which a blood sample obtained by diluting capillary blood with a hemolytic reagent is analyzed in a particle analyzer, as shown in the leukocyte volume histogram of
FIG. 12 , the tailing portion T of the ghost peak G and the leading portion R of the leukocyte peak W overlap with each other over a relatively wide range. For this reason, leukocytes cannot be counted with high accuracy. This is because platelet aggregates are miscounted over the range from the tailing portion T of the ghost peak G to the leading portion R of the leukocyte peak W. - Collection of capillary blood is performed by pricking a fingertip or an earlobe with a lancet to obtain a very small amount of blood and is advantageous in that blood can be collected in a simple and rapid manner. However, a tissue solution is likely to be incorporated into the blood being collected, and thus platelets may aggregate rapidly after collection.
- Ethylenediamine tetraacetate has the function of inhibiting the aggregation of platelets, but does not have the function of dissociating platelet aggregates. Thus, even when capillary blood in which platelets aggregate rapidly after blood collection is treated with a hemolytic reagent containing ethylenediamine tetraacetate, platelet aggregates cannot be dissociated.
- The present invention has been made in order to solve the above technical problem, and it is an object of the present invention to provide a novel reagent for blood cell counting and a blood analysis method, which enable blood cells such as leukocytes to be counted with high accuracy by dissociating platelet aggregates in capillary blood collected from a living body.
- The reagent for blood cell counting according to the present invention is used to dilute capillary blood collected from a living body to prepare a blood sample in order to count blood cells in the collected capillary blood using a particle analyzer, and is characterized in that it is an aqueous solution containing a chloroquine salt.
- The reagent for blood cell counting according to the present invention is used to dilute “capillary blood” collected from a living body to prepare a blood sample in order to count blood cells such as leukocytes in the collected capillary blood using a “particle analyzer”. As used herein, the term “capillary blood” means blood obtained by pricking a fingertip or an earlobe with a lancet (fingertip blood or earlobe blood). The term “particle analyzer” means a particle analyzer (flow cytometer or coulter counter) that uses an analysis method called flow cytometry in which fine particles are dispersed in a fluid which is then allowed to flow thinly while individual particles in the fluid are counted. The particle analyzer may be broadly divided into two types: one that uses an optical detection method in which light scattering or fluorescence is detected; and the other that uses an electrical resistance detection method in which a change in impedance when particles pass through a thin hole is detected. The electrical resistance detection method is superior in that it is simple and convenient.
- The “chloroquine salt” that is contained in the reagent for blood cell counting according to the present invention serves to dissociate platelet aggregates in capillary blood and refers to a compound having a quinoline backbone and containing a chloro group. Particularly, salts of chloroquinoline derivatives which have a chloro group introduced at
position 7 of the quinoline backbone and an amino group introduced at position 4 of the quinoline backbone are preferably used in the present invention. Specific examples of the chloroquine salt include chloroquine diphosphate (7-chloro-4-[4-(diethylamino)-1-methylbutylamino]quinoline diphosphate), hydroxychloroquine sulfate (7-chloro-4-[4-N-ethyl-N-(2-hydroxyethyl)amino]-1-methylbutylamino)quinoline sulfate), and the like. - The reagent for blood cell counting according to the present invention preferably contains 10 g/L or more of the chloroquine salt.
- In a conventional method of counting leukocytes, a dilution process of diluting blood collected from a living body about 100-500-fold with a reagent is carried out. It has been found that when a very small amount of a chloroquine salt is contained in a reagent, platelet aggregates can be dissociated by carrying out the dilution process using the reagent. With respect to the dissociation of platelet aggregates, the upper limit of the concentration of the chloroquine salt in the reagent is not specifically limited. However, as the concentration of the chloroquine salt increases, the cost of the reagent increases. For this reason, the upper limit of the concentration of the chloroquine salt is preferably limited to 100 g/L.
- The reagent for blood cell counting according to the present invention preferably further contains a surfactant having hemolytic activity. As the surfactant, any surfactant may be used without particular limitation, so long as it breaks the membrane of blood cells when mixed with blood, and lyses erythrocytes in blood while lysing leukocytes to leave bare nuclei. The surfactant may be ionic or nonionic. The ionic surfactant is preferably an anionic surfactant. The anionic surfactant is preferably a quaternary ammonium salt. Specific examples of the quaternary ammonium salt include chlorides or bromides of hexadecyltrimethyl ammonium or dodecyltrimethyl ammonium. Meanwhile, specific examples of the nonionic surfactant include saponin.
- Preferably, the reagent for blood cell counting according to the present invention contains a chloroquine salt such that it can dissociate platelet aggregates. In addition, the concentration of a surfactant in the reagent for blood cell counting is limited such that a leukocyte peak in a leukocyte volume histogram will be clear.
- In this regard, the reagent for blood cell counting according to the present invention preferably contains 10-50 g/L of the surfactant.
- It has been found that if the reagent for blood cell counting contains 10 g/L or more of the surfactant, it can break the membrane of blood cells when the dilution process is carried out using the reagent, and it can lyse erythrocytes in blood in the dilution step while lysing leukocytes to leave bare nuclei. On the other hand, if the concentration of the surfactant in the reagent for blood cell counting is more than 50 g/L, the volume of leukocytes in the blood sample will decrease. For this reason, the concentration of the surfactant in the reagent for blood cell counting according to the present invention is preferably set in the range of 10 to 50 g/L (more preferably 20 to 40 g/L).
- In addition, the reagent for blood cell counting according to the present invention preferably further contains an “electrolyte” such that the osmotic pressure of the reagent is adjusted to 200-600 Osm/kg.
- The “electrolyte” is not specifically limited, so long as it is ionized to cations, such as sodium ions, potassium ions or magnesium ions, and anions such as chloride ions, bromide ions or phosphate ions, when it is dissolved in water. Specific examples of the electrolyte include sodium chloride, sodium bromide, potassium chloride, potassium bromide, calcium chloride, calcium bromide, magnesium chloride, magnesium bromide, sodium phosphate, potassium phosphate, and the like.
- If the concentration of the electrolyte in the reagent for blood cell counting is so low that the osmotic pressure of the reagent is less than 200 Osm/kg, the expansion and degradation of leukocytes will result. On the other hand, if the concentration of the electrolyte in the reagent for blood cell counting is so excessively high that the osmotic pressure of the reagent is more than 600 Osm/kg, the volume of leukocytes will decrease such that the leukocyte peak will shift to the lower volume side so as to approach the ghost peak. For this reason, according to the present invention, the osmotic pressure of the reagent for blood cell counting is preferably adjusted in the range of 200 to 600 Osm/kg (more preferably, 300 to 400 Osm/kg). In this case, the leukocyte peak can be prevented from being excessively close to the ghost peak.
- Preferably, the reagent for blood cell counting according to the present invention is configured such that a minimum value of a relative frequency of valleys in distribution where the tailing portion of a ghost peak and the leading portion of a leukocyte peak in a leukocyte volume histogram, which is obtained when introducing the blood sample into the particle analyzer, overlap with each other lies within a particle volume range of 35 to 50 fL.
- When the minimum value of the relative frequency of the valleys in the distribution where the tailing portion of the ghost peak and the leading portion of the leukocyte peak in the leukocyte volume histogram, which is obtained by counting leukocytes using the particle analyzer, overlap with each other lies within the particle volume range of 35 to 50 fL, a clear leukocyte peak can be obtained and the leukocyte peak can be prevented from being excessively close to the ghost peak, so that the miscounting derived from the platelet aggregates can be reduced. Thus, leukocytes in the blood sample can be counted with high accuracy.
- In addition, the reagent for blood cell counting according to the present invention preferably further contains an “anti-aggregation agent”.
- As used herein, the term “anti-aggregation agent” means one having the property of inhibiting the aggregation of platelets. When the reagent for blood cell counting according to the present invention further contains the anti-aggregation agent, platelets (including platelets dissociated by the chloroquine salt) can be prevented from aggregating. Specific examples of the anti-aggregation agent include salts of ethylenediamine tetraacetate (EDTA), for example, EDTA-2Na (disodium salt), EDTA-2K (dipotassium salt), EDTA-3Na (trisodium salt) or EDTA-3K (tripotassium salt), heparin, acetylsalicylic acid, magnesium sulfate, etc. The concentration of the anti-aggregation agent in the reagent for blood cell counting is preferably 0.01-0.2 g/L, but is not specifically limited thereto.
- The reagent for blood cell counting according to the present invention is preferably diluted with a buffer solution in order to stabilize the pH (hydrogen ion concentration) of the reagent. In addition, the reagent for blood cell counting according to the present invention may further contain a nonionic surfactant for adjusting surface tension, a pH-adjusting agent for adjusting pH, a membrane protective agent for stabilizing bare nuclei remaining after lysis of leukocytes, a preservative for increasing storage stability, and other various additives.
- Specific examples of the “buffer solution” include acetate buffer, phosphate buffer, citrate buffer, borate buffer, tartrate buffer, and tris buffer. Specific examples of the pH-adjusting agent include sodium hydroxide and hydrochloric acid.
- The “nonionic surfactant” for adjusting surface tension is not specifically limited, so long as it contains a hydrophilic group and a hydrophobic group in the molecule and has the property of lowering the surface tension of the reagent for blood cell counting. Specific examples of the nonionic surfactant include “ether-type nonionic surfactants”, such as polyoxyethylene decyl ether, polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene octylphenyl ether or polyoxyethylene nonylphenyl ether; and ester-type nonionic surfactants (including etherester-type nonionic surfactants), such as polyoxyethylene lauric acid ester, polyoxyethylene oleic acid ester, polyoxyethylene sorbitan lauric acid ester, polyoxyethylene sorbitan oleic acid ester, sorbitan mono- (or di-) oleic acid ester, sorbitan mono- (or di-) lauric acid ester, or sorbitan mono- (or di-) isostearic acid ester.
- Specific examples of the “preservative” include sodium azide, sodium omadine, Kathon CG, ROCIMA® 553, thimerosal and the like. Specific examples of the “membrane protective agent” include lower alcohols such as isopropyl alcohol, glutaraldehyde, dimethyl urea, glucose and the like.
- The blood analysis method of the present invention is a blood analysis method in which blood cells such as leukocytes, which are contained in capillary blood collected from a living body, are counted in a particle analyzer, the blood analysis method comprising the steps of: collecting capillary blood from a living body; diluting the collected capillary blood with the reagent for blood cell counting according to the present invention to prepare a blood sample; and introducing the blood sample into the particle analyzer and counting leukocytes in the blood sample using the particle analyzer.
- Preferably, in the blood analysis method of the present invention, the step of counting the leukocytes comprises determining a count start volume in a particle volume range of 35 to 50 fL and counting particles having a volume equal to or larger than the determined count start volume as leukocytes.
- Counting of leukocytes in the particle analyzer is performed by considering particles having a specific range of volume in the blood sample as leukocytes, and counting the particles one by one. That is, the “count start volume” as used herein means the lower limit of the specific range of volume. In addition, the upper limit of the specific range in counting of leukocytes in the particle analyzer is the simple end point of the counting and is not a particularly important factor. In general, the upper limit of the specific range in the counting is about 300-500 fL.
- According to the present invention, platelet aggregates in capillary blood collected from a living body can be dissociated, and thus blood cells such as leukocytes can be counted with high accuracy using a particle analyzer.
-
FIG. 1 is a top view showing a measurement unit in a micro blood cell counter. -
FIG. 2 is a side view showing a measurement unit in a micro blood cell counter. -
FIG. 3( a) is a sectional view showing a dilution bottle in a micro blood cell counter;FIG. 3( b) is a bottom view of the dilution bottle;FIG. 3( c) is a sectional view showing a state in which a dilution bottle according to another embodiment is set with a bottle guide into a blood counter;FIG. 3( d) is a partial sectional view showing another embodiment of the dilution bottle shown inFIG. 3( c); andFIG. 3( e) is a partial sectional view showing still another embodiment of the dilution bottle shown inFIG. 3( c). -
FIG. 4 is a top view showing a body in a micro blood cell counter. -
FIG. 5 is a side view showing a body in a micro blood cell counter. -
FIG. 6 is a perspective view showing a measurement unit (provided with a dilution bottle) inserted into a body in a micro blood cell counter. -
FIGS. 7( a) and 7(b) are leukocyte volume histograms obtained by measuring blood samples diluted with the inventive reagents for blood cell counting according to Examples 1 and 2, respectively; andFIG. 7( c) is a leukocyte volume histogram obtained by measuring a blood sample diluted with a reagent for blood cell counting according to Comparative Example 1. -
FIGS. 8( a), 8(b), 8(c) and 8(d) are leukocyte volume histograms obtained by measuring blood samples diluted with the inventive reagents for blood cell counting according to Examples 3, 1, 4 and 5, respectively. -
FIGS. 9( a), 9(b) and 9(c) are leukocyte volume histograms obtained by measuring blood samples diluted with the inventive reagents for cell blood counting according to Examples 6, 1 and 7, respectively; andFIGS. 9( d) and 9(e) are leukocyte volume histograms obtained by measuring blood samples diluted with reagents for blood cell counting according to Comparative Examples 2 and 3, respectively. -
FIGS. 10( a), 10(b) and 10(c) are leukocyte volume histograms obtained by measuring blood samples diluted with the inventive reagents for blood cell counting according to Examples 8, 1 and 9, respectively; andFIGS. 10( d) and 10(e) are leukocyte volume histograms obtained by measuring blood cells diluted with reagents for blood cell counting according to Comparative Examples 4 and 5, respectively. -
FIG. 11 is a leukocyte volume histogram obtained by measuring a blood sample prepared by diluting venous blood with a reagent for blood cell counting according to the prior art. -
FIG. 12 is a leukocyte volume histogram obtained by measuring a blood sample prepared by diluting capillary blood with a reagent for blood cell counting according to the prior art. - Hereinafter, one embodiment of the present invention will be described, but is not intended to limit the scope of the present invention.
- A particle analyzer used in this embodiment was a micro blood cell counter (trade name (tentative name): Palm-LC; manufactured by Horiba Manufacturing Co., Ltd.).
- —
Measurement unit 1— -
FIGS. 1 and 2 show ameasurement unit 1 in a micro blood cell counter. Themeasurement unit 1 is prepared in the form of a cartridge made of a resin such as polymethylmethacrylate (PMMA). Aresin substrate 2 of themeasurement unit 1 comprises: afluid path 3 for connection to the outside, one end of which is connected to apump connection port 17; aliquid storage cell 7 connected to the other end of thefluid path 3 and having fluid paths defined bywalls cell 9 connected to theliquid storage cell 7 through afluid path 8; adetection fluid path 11 connected to the absorbance-measuringcell 9 through afluid path 10; a capillary 13 connected to thedetection fluid path 11 through afluid path 12 having an approximately S-shape; and asensor mounting portion 16 provided between thefluid path 10 and thefluid path 12. - Each of the elements formed on the
resin substrate 2 has a predetermined depth and width. As shown inFIG. 2 , theresin substrate 2 includes aresin substrate 2 a and aresin substrate 2 b. On theresin substrate 2 a, theliquid storage cell 7 is formed with a depth of, for example, about 4 mm, and the absorbance-measuringcell 9 is also formed with a predetermined depth. On theresin substrate 2 b, thefluid path 3 for connection to the outside, thefluid paths detection fluid path 11 and a capillary-receivingfluid path 18 are formed with a width and depth of, for example, about 1 mm and about 1 mm, respectively. In addition, thesensor mounting portion 16 is formed on theresin substrate 2 b. Moreover, the allocation of the fluid paths and other elements formed on theresin substrates resin substrates - After the elements are formed on the
resin substrates resin substrate 2 a and theresin substrate 2 b are bonded to each other by means of, for example, an adhesive or a double-sided adhesive tape, so as to prevent liquid leakage. Subsequently, the capillary 13 made of, for example, glass, is buried in the capillary-receivingfluid path 18, and is fixed to the capillary receivingfluid path 18 by, for example, an adhesive, while the outer circumferential surface of the capillary 13 and the inner circumferential surface of the capillary-receiving fluid path are sealed. - Subsequently, the center of a
bottle guide 19 is aligned with the center of the capillary 13. In this state, thebottle guide 19 is bonded to the end sides of theresin substrates pump connection port 17 is connected to thefluid path 3 for connection to the outside 3, and in this state, thepump connection port 17 is bonded to the end sides of theresin substrates sensor chip 145 is provided withelectrodes sensor substrate 20 having thesensor chip 145 mounted thereon is attached to asensor mounting portion 16 to provide a sensor unit, thereby completing themeasurement unit 1 in this micro blood cell counter. Theelectrodes lines sensor chip 145 is mounted on thesensor substrate 20, whereby a signal in the sensor unit can be drawn from the lead lines 21 and 22. In the above description, thesensor chip 145 is attached to thesensor mounting portion 16 in a later step. However, thesensor chip 145 may be formed on theresin substrate electrodes sensor chip 145 by sputtering. -
FIGS. 3( a) and 3(b) show adilution bottle 23. Thedilution bottle 23 comprises: acontainer 24 for receiving a reagent “S” for blood cell counting; anair hole 27 formed through the top of thecontainer 24; aseal 26 for sealing theair hole 27; and amembrane 25 attached to the bottom of thecontainer 24. Thedilution bottle 23 receives the reagent “S” for blood cell counting in thecontainer 24 and is sealed by theseal 26 and themembrane 25. Thedilution bottle 23 is not limited to the one shown inFIGS. 3( a) and 3(b). For example, in thedilution bottle 23 shown inFIG. 3 c, the lower portion of thecontainer 24 has a reduced diameter, aguide portion 28 is provided such that it extends downward from themembrane 25, and thecontainer 24, the membrane and theguide portion 28 are formed integrally with each other. Thisdilution bottle 23 is configured such that, when thecontainer 24 is allowed to slide along thebottle guide 19, theguide portion 28 comes into close contact with the outer circumferential side of the capillary 13 such that it can guide the correspondingcapillary 13 to themembrane 25. In addition, in thisdilution bottle 23, anatmosphere opening portion 261 consisting of, for example, a resin check valve, is provided in the central portion of theseal 26, and when or before the capillary 13 is inserted into and passed through themembrane 25, a ventilation needle (not shown) is inserted into and passed through theatmosphere opening portion 261 such that the inside of the container is ventilated.FIG. 3( c) shows that thecontainer 24, themembrane 25 and theguide portion 28 are formed integrally with each other. However, as shown inFIG. 3( d), thedilution bottle 23 may also be constructed by attaching themembrane 25 to the inlet at the bottom of thecontainer 24 and fitting aseparate guide member 281 therewith. In addition, as shown inFIG. 3( e), thedilution bottle 23 may also be constructed such that the reagent “S” for blood cell counting is received in thecontainer 24 by pressing asphere 29 into the position corresponding to themembrane 25 and such that thesphere 29 is pressed into thecontainer 24 by the capillary 13 in the measurement process so as to open thecontainer 24. The capacity of thecontainer 24 is not specifically limited, because it varies depending on the type of micro blood cell counter or the dilution factor of the reagent “S” for blood cell counting. For example, the capacity of thecontainer 24 may preferably be 0.1-2 ml, more preferably 0.3-1.0 ml, and even more preferably 0.5 ml. -
FIGS. 4 and 5 show abody 100 of the micro blood cell counter. Thebody 100 of the micro blood cell counter is covered with acase 51, and three-wayelectronic valves diaphragm pump 55,batteries circuit board 62 and acartridge setting portion 63 are provided in thecase 51. In addition, atransparent plate 60 is attached in a window frame formed on the top surface of thecase 51 such that the display of theLCD 61 can be seen from the outside. In addition, abattery cover 65 which is open or closed in order to set or replace thebatteries case 51. - The discharge (pressure) side of the
diaphragm pump 55 is connected to the common port of the three-wayelectronic valve 53, and the suction (vacuum) side of thediaphragm pump 55 is connected to the common port of the three-wayelectronic value 54. In addition, the NO port (normally open port) of the three-wayelectronic valve 53 is connected to the NC port (normally closed port) of the three-way valve 54, and the NC port of the three-wayelectronic valve 53 is connected to the NO port of the three-wayelectronic valve 54. - In addition, the line that connects the NO port of the three-way
electronic valve 53 with the NC port of the three-wayelectronic valve 54 is configured such that thepump connection port 17 of the cartridge-type measurement unit 1 is connected thereto when themeasurement unit 1 prepared in the form of the cartridge is set in the cartridge-settingportion 63. Operating power is supplied to the three-wayelectronic valves diaphragm pump 55 and theLCD 61 by thebatteries electronic valves diaphragm pump 55 and theLCD 61 are controlled by a control circuit provide on thecircuit board 62. Also, a signal indicating the variation in impedance is supplied to an operational circuit provided on thecircuit board 62, whereby blood cells in the blood sample are measured, and the results of the measurement are displayed in theLCD 61. - Hereinafter, the blood analysis method of the present invention, which uses the micro blood cell counter having the above-described configuration, will be described.
- In the blood analysis method of the present invention, a step of collecting capillary blood from a living body is first carried out. In this embodiment, the blood collecting step is carried out by pricking, for example, the fingertip of a subject (living body) with the tip of the capillary and drawing capillary blood (1 μL) into the capillary 13 by a capillary phenomenon.
- Then, a step of diluting the collected capillary blood with the reagent “S” for blood cell counting of the present invention is carried out to prepare a blood sample. In this embodiment, in this diluting step, the
dilution bottle 23 containing the reagent “S” for blood cell counting is allowed to slide along thebottle guide 19, and themembrane 25 of thedilution bottle 23 is broken at the tip of the capillary 13, whereby the tip of the capillary 13 is inserted into thedilution bottle 23. Then, theseal 26 of thedilution bottle 23 is removed. Thus, thedilution bottle 23 is open to the atmosphere through the hole at the top thereof. - When the
measurement unit 1 is inserted and set in thebody 100 of the micro blood cell counter (seeFIG. 6 ), thepump connection port 17 is connected to thediaphragm pump 55 accommodated in thebody 100 of the micro blood cell counter. Also, thesensor substrate 20 is electrically connected to an impedance measurement circuit provided in thebody 100. In addition, when thediaphragm pump 55 is operated to apply pressure to the inside of the capillary 13 through thepump connection portion 17, thefluid path 3 for connection to the outside, theliquid storage cell 7, thefluid path 8, the absorbance-measuringcell 9, thefluid path 10, thedetection fluid path 11 and thefluid path 12, the capillary blood in the capillary 13 is then pressure-introduced into thedilution bottle 23. At this time, bubbling occurs in thedilution bottle 23, so that the capillary blood and the reagent “S” for blood cell counting are mixed, thereby obtaining a blood sample diluted with the reagent “S” for blood cell counting (dilution factor: 251). - After the diluting step, a step of counting leukocytes in the blood sample is carried out according to the present invention. In this embodiment, in the counting step, the
diaphragm pump 55 is operated to apply a vacuum to the inside of the capillary 13 through thepump connection port 17, thefluid path 3 for connection to the outside, theliquid storage cell 7, thefluid path 8, the absorbance-measuringcell 9, thefluid path 10, thedetection fluid path 11 and thefluid path 12. Then, the blood sample in thedilution bottle 23 is introduced into thedetection fluid path 11 through the capillary 13 and thefluid path 12. Herein, the variation in impedance between theelectrodes detection fluid path 11 occurs, and the micro blood cell counter measures particles in the blood sample on the basis of this variation in impedance. - The diluted blood passed through the
detection fluid path 11 flows to the absorbance-measuringcell 9 through thefluid path 10. When the amount of hemoglobin is to be measured in addition to the counting of leukocytes, the amount of hemoglobin in the blood sample can be measured by measuring the absorbance of the absorbance-measuringcell 9 with an optical sensor (not shown). In addition, the blood sample passed through the absorbance-measuringcell 9 flows to theliquid storage cell 7 through thefluid path 8 and is collected as waste. After completion of the measuring step, themeasurement unit 1 is separated from the body of the micro blood cell unit and wasted together with the blood sample collected in theliquid storage cell 7. - 20 g/L of chloroquine diphosphate as a chloroquine salt and 36.6 g/L of hexadecyltrimethylammonium bromide as a quaternary ammonium salt were dissolved in 0.5M phosphate buffer solution, and sodium chloride as an electrolyte was added thereto, thereby preparing a reagent for cell blood counting according to the present invention, which had an osmotic pressure of 390 Osm/kg. Herein, the osmotic pressure was measured with an osmometer (Osmostat OM-6020; Daiichikagakuco, Kyoto, Japan).
- A reagent for blood cell counting according to the present invention, which had an osmotic pressure of 390 Osm/kg, was prepared in the same manner as Example 1, except that dodecyltrimethyl ammonium chloride (36.6 g/L) was used as the quaternary ammonium.
- A reagent for blood cell counting having an osmotic pressure of 390 Osm/kg was prepared in the same manner as Example 1, except that the chloroquine salt was not used.
- The inventive reagents for blood cell counting according to Examples 1 and 2 and the reagent for blood cell counting according to Comparative Example 1 were placed and sealed in
different dilution bottles 23. Then, the fingertip of a subject was pricked with the top of the capillary 13 provided in themeasurement unit 1 to draw capillary blood into the capillary 13, and the top of the capillary 13 was inserted into thedilution bottle 23. Then, themeasurement unit 1 was inserted into the cartridge-settingportion 63 of the micro blood cell counter, thereby performing the blood analysis method of the present invention.FIGS. 7( a)-7(c) show the leukocyte volume histograms obtained by this analysis method. - The leukocyte volume histograms shown in
FIGS. 7( a) and 7(b) were those obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Examples 1 and 2, respectively. In the leukocyte volume histograms shown inFIGS. 7( a) and 7(b), it was seen that the ghost noise “G” and the leukocyte peak “W” were clearly isolated from each other and that platelet aggregates had little or no influence on miscounting. In addition, it was observed that a minimum value of a relative frequency of valleys in distribution where the tailing portion of the ghost peak and the leading portion of the leukocyte peak in the histogram overlap with each other lies within a particle volume range of 35 to 50 fL. Thus, leukocytes in the blood samples can be counted with high accuracy by determining a count start volume within a particle volume range of 35 to 50 fL and counting particles having a volume equal to or larger than the determined count start volume as leukocytes. - Meanwhile,
FIG. 7( c) shows a leukocyte volume histogram obtained by measuring the blood sample diluted with the reagent for blood cell counting according to Comparative Example 1. In this leukocyte volume histogram, the ghost peak was significantly larger, and the tailing portion thereof was shifted toward the higher volume side and overlapped with the leading portion of the leukocyte peak over a wide range. Thus, it was found that even when the count start volume is determined within a particle volume range of 35 to 50 fL, miscounting derived from platelet aggregates occurs, resulting in that leukocytes cannot be counted with high accuracy. - Reagents for blood cell counting were prepared in the same manner as Example 1, except that the concentration of the chloroquine salt was changed to 10 g/L (Example 3), 40 g/L (Example 4) and 80 g/L (Example 5).
- The inventive blood analysis method for measuring capillary blood was carried out using each of the reagents for blood cell counting according to Examples 3 to 5 in addition to the reagent for blood cell counting according to Example 1.
FIGS. 8( a)-8(d) shows the obtained leukocyte volume histograms. -
FIGS. 8( a), 8(b), 8(c) and 8(d) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Examples 3, 1, 4 and 5, respectively. - As can be seen from the results in
FIGS. 8( a)-8(d), when the concentration of the chloroquine salt in the reagent for blood cell counting is 10 g/L or higher, platelet aggregates are dissociated so that the range in which the tailing portion of the ghost peak “G” and the leading portion “R” of the leukocyte peak “W” overlap with each other becomes narrower, suggesting that the influence of the ghost peak on miscounting is substantially eliminated. - Reagents for blood cell counting were prepared in the same manner as Example 1, except that the concentration of the quaternary ammonium salt was changed to 10 g/L (Example 6) and 50 g/L (Example 7).
- Reagents for blood cell counting were prepared in the same manner as Example 1, except that the concentration of the quaternary ammonium salt was changed to 5 g/L (Comparative Example 2) and 100 g/L (Comparative Example 3).
- The inventive blood analysis method for measuring capillary blood was carried out using each of the reagents for blood cell counting according to Examples 6 and 7 and Comparative Examples 2 and 3 in addition to the reagent for blood cell counting according to Example 1.
FIGS. 9( a)-9(e) shows the obtained leukocyte volume histograms. -
FIGS. 9( a), 9(b) and 9(c) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Examples 6, 1 and 7, respectively. Also,FIGS. 9( d) and 9(e) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Comparative Examples 2 and 3, respectively. - From the results in
FIGS. 9( a)-9(e), it was observed that when the concentration of the quaternary ammonium salt in the reagent for blood cell counting was less than 10 g/L, a clear leukocyte peak was not obtained. On the other hand, when the concentration of the quaternary ammonium salt in the reagent for blood cell counting was more than 50 g/L, the leukocyte peak was shifted to the lower volume side, and thus the tailing portion of the ghost peak and the leading portion of the leukocyte peak were widely overlapped with each other. - Thus, it was confirmed that when the concentration of the quaternary ammonium salt in the reagent for blood cell counting is 10-50 g/L, a minimum value of a relative frequency of valleys in distribution where the tailing portion of the ghost peak and the leading portion of the leukocyte peak in the histogram overlap with each other can lie within a particle volume range of 35 to 50 fL.
- Reagents for blood cell counting according to the present invention were prepared in the same manner as Example 1, except that the osmotic pressures of the reagents were adjusted to 200 Osm/kg (Example 8) and 600 Osm/kg (Example 9) by changing the concentration of NaCl serving as the electrolyte.
- Reagents for blood cell counting were prepared in the same manner as Example 1, except that the osmotic pressures of the reagents were adjusted to 100 Osm/kg (Comparative Example 4) and 1000 Osm/kg (Comparative Example 9) by changing the concentration of NaCl serving as the electrolyte.
- The inventive blood analysis method for measuring capillary blood was carried out using each of the reagents for blood cell counting according to Examples 8 and 9 and Comparative Examples 4 and 5 in addition to the reagent for blood cell counting according to Example 1.
FIGS. 10( a)-10(e) shows the obtained leukocyte volume histograms. -
FIGS. 10( a), 10(b) and 10(c) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Examples 8, 1 and 9, respectively. Also,FIGS. 10( d) and 10(e) show leukocyte volume histograms obtained by measuring the blood samples diluted with the inventive reagents for blood cell counting according to Comparative Examples 4 and 5, respectively. - From the results in
FIGS. 10( a)-10(e), it was seen that when the osmotic pressure of the reagent for blood cell counting was less than 200 Osm/kg, a clear leukocyte peak was not obtained. On the other hand, when the osmotic pressure of the reagent for blood cell counting was more than 600 Osm/kg, the leukocyte peak was shifted to the lower volume side, and thus the tailing portion of the ghost peak and the leading portion of the leukocyte peak were widely overlapped with each other. - Thus, it was confirmed that when the osmotic pressure of the reagent for blood cell counting is 200˜600 Osm/kg, a minimum value of a relative frequency of valleys in distribution where the tailing portion of the ghost peak and the leading portion of the leukocyte peak in the histogram overlap with each other can lie within a particle volume range of 35 to 50 fL.
- The present invention can be carried out in various forms without departing from the spirit or main features thereof. Therefore, the foregoing embodiments are merely exemplary in all points and should not be restrictedly interpreted. The scope of the present invention is defined by the claims and is not restricted by the text of the specification. Further, all modifications, various improvements, substitutions and alterations belonging to the equivalent range of the claims are within the scope of the present invention.
- The present invention enables leukocytes in capillary blood to be counted with high accuracy. In addition, the present invention can also be used to analyze other blood components, such as platelets or erythrocytes.
Claims (20)
1. A reagent for blood cell counting which is used to dilute capillary blood collected from a living body to prepare a blood sample in order to count blood cells in the collected capillary blood using a particle analyzer, wherein the reagent for blood cell counting is an aqueous solution containing a chloroquine salt.
2. The reagent of claim 1 , wherein the chloroquine salt is contained at a concentration of 10 g/L or more.
3. The reagent of claim 1 , wherein the reagent further contains a surfactant having hemolytic activity.
4. The reagent of claim 2 , wherein the reagent further contains a surfactant having hemolytic activity.
5. The reagent of claim 3 , wherein the surfactant is an anionic surfactant.
6. The reagent of claim 4 , wherein the surfactant is an anionic surfactant.
7. The reagent of claim 3 , wherein the surfactant is contained at a concentration of 10-50 g/L.
8. The reagent of claim 6 , wherein the surfactant is contained at a concentration of 10-50 g/L.
9. The reagent of claim 1 , wherein the reagent further contains an electrolyte so as to adjust an osmotic pressure of the reagent to 200-600 Osm/kg.
10. The reagent of claim 8 , wherein the reagent further contains an electrolyte so as to adjust an osmotic pressure of the reagent to 200-600 Osm/kg.
11. The reagent of claim 1 , wherein a minimum value of a relative frequency of valleys in distribution where a tailing portion of a ghost peak and a leading portion of a leukocyte peak in a leukocyte volume histogram, which is obtained when introducing the blood sample into the particle analyzer, overlap with each other lies within a particle volume range of 35 to 50 fL.
12. The reagent of claim 10 , wherein a minimum value of a relative frequency of valleys in distribution where a tailing portion of a ghost peak and a leading portion of a leukocyte peak in a leukocyte volume histogram, which is obtained when introducing the blood sample into the particle analyzer, overlap with each other lies within a particle volume range of 35 to 50 fL.
13. The reagent of claim 1 , wherein the reagent further contains an anti-aggregation agent.
14. The reagent of claim 12 , wherein the reagent further contains an anti-aggregation agent.
15. A blood analysis method in which blood cells in capillary blood collected from a living body are counted by a particle analyzer, the method comprising:
collecting the capillary blood from the living body;
diluting the collected capillary blood with a reagent for blood cell counting, which is an aqueous solution containing a chloroquine salt, thereby preparing a blood sample; and
introducing the blood sample into the particle analyzer and counting leukocytes in the blood sample by the particle analyzer.
16. The method of claim 15 , wherein the counting of the leukocytes comprises determining a count start volume in a particle volume range of 35 to 50 fL and counting particles having a volume equal to or larger than the determined count start volume as the leukocytes.
17. A dilution bottle in which a reagent for blood cell counting, which is an aqueous solution containing a chloroquine salt, is received and sealed.
18. The dilution bottle of claim 17 , wherein the reagent for blood cell counting is received in an amount of 100-500 times based on a volume of a blood sample collected by a particle analyzer that uses the dilution bottle.
19. The dilution bottle of claim 18 , wherein a membrane which is broken by a tip of a capillary provided in the particle analyzer is provided at an inlet formed at a bottom of a container of the dilution bottle, and a seal is attached to an air hole formed at a top of the container to seal the reagent for blood cell counting.
20. A particle analyzer configured to determine a count start volume in a particle volume range of 35 to 50 fL and to count particles having a volume equal to or larger than the determined count start volume as leukocytes included in capillary blood collected from a living body in a blood cell counting process that uses a reagent for blood cell counting, which is an aqueous solution containing a chloroquine salt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/033,221 US8927228B2 (en) | 2011-05-10 | 2013-09-20 | Reagent for blood cell counting and blood analysis method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-105611 | 2011-05-10 | ||
JP2011105611A JP5559096B2 (en) | 2011-05-10 | 2011-05-10 | Blood cell counting reagent and blood test method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/033,221 Continuation US8927228B2 (en) | 2011-05-10 | 2013-09-20 | Reagent for blood cell counting and blood analysis method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120288889A1 true US20120288889A1 (en) | 2012-11-15 |
Family
ID=46084881
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/467,840 Abandoned US20120288889A1 (en) | 2011-05-10 | 2012-05-09 | Reagent for blood cell counting and blood analysis method |
US14/033,221 Expired - Fee Related US8927228B2 (en) | 2011-05-10 | 2013-09-20 | Reagent for blood cell counting and blood analysis method |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/033,221 Expired - Fee Related US8927228B2 (en) | 2011-05-10 | 2013-09-20 | Reagent for blood cell counting and blood analysis method |
Country Status (4)
Country | Link |
---|---|
US (2) | US20120288889A1 (en) |
EP (1) | EP2522999B1 (en) |
JP (1) | JP5559096B2 (en) |
CN (1) | CN102778425A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10638963B2 (en) * | 2017-01-10 | 2020-05-05 | Drawbridge Health, Inc. | Devices, systems, and methods for sample collection |
CN112014196A (en) * | 2020-08-15 | 2020-12-01 | 湖南伊鸿健康科技有限公司 | Dilution method for classifying and counting white blood cells |
US11266337B2 (en) | 2015-09-09 | 2022-03-08 | Drawbridge Health, Inc. | Systems, methods, and devices for sample collection, stabilization and preservation |
US11603254B1 (en) * | 2019-10-18 | 2023-03-14 | University Of South Florida | Miniature pressure-driven pumps |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109923418B (en) * | 2016-11-11 | 2020-12-11 | 布尔医疗设备有限公司 | Method and apparatus for platelet counting in capillary vessels |
WO2019079363A1 (en) * | 2017-10-18 | 2019-04-25 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
WO2020113527A1 (en) * | 2018-12-06 | 2020-06-11 | 深圳迈瑞生物医疗电子股份有限公司 | Method for detecting white blood cells, blood cell analyzer, and storage medium |
CN113959911A (en) * | 2020-07-20 | 2022-01-21 | 深圳迈瑞生物医疗电子股份有限公司 | Detection method and reagent for resisting platelet aggregation interference and application thereof |
CN113959912A (en) * | 2020-07-20 | 2022-01-21 | 深圳迈瑞生物医疗电子股份有限公司 | Leukocyte detection method and reagent for resisting platelet aggregation interference and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529705A (en) * | 1983-06-06 | 1985-07-16 | Coulter Electronics, Inc. | Reagent for combined diluting and lysing whole blood |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0695092B2 (en) * | 1989-10-30 | 1994-11-24 | 隆己 永田 | Anticoagulant for blood cell counting |
JP3118625B2 (en) * | 1994-01-11 | 2000-12-18 | 長瀬産業株式会社 | Blood cell separation method |
JP3324050B2 (en) * | 1994-10-31 | 2002-09-17 | 日本光電工業株式会社 | Leukocyte classification reagent and leukocyte classification method |
JP3743918B2 (en) * | 1996-03-22 | 2006-02-08 | デイド、ベーリング、インコーポレイテッド | Combination reagent holding and testing equipment |
DE19634313A1 (en) * | 1996-08-24 | 1998-02-26 | Behringwerke Ag | Method for stabilizing platelets |
JP2001033442A (en) * | 1999-07-26 | 2001-02-09 | A & T:Kk | Immunoassay of modification group of modified hemoglobin |
FR2891911B1 (en) * | 2005-10-07 | 2008-04-25 | Horiba Abx Sas Soc Par Actions | "MODULAR DEVICE FOR THE ANALYSIS OF A BIOLOGICAL FLUID, PARTICULARLY BLOOD" |
SE531873C2 (en) * | 2007-11-12 | 2009-09-01 | Lifeassays Ab | Device for biochemical processing and analysis of sample liquid |
-
2011
- 2011-05-10 JP JP2011105611A patent/JP5559096B2/en not_active Expired - Fee Related
-
2012
- 2012-05-09 US US13/467,840 patent/US20120288889A1/en not_active Abandoned
- 2012-05-10 EP EP12167421.2A patent/EP2522999B1/en not_active Not-in-force
- 2012-05-10 CN CN2012101442096A patent/CN102778425A/en active Pending
-
2013
- 2013-09-20 US US14/033,221 patent/US8927228B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529705A (en) * | 1983-06-06 | 1985-07-16 | Coulter Electronics, Inc. | Reagent for combined diluting and lysing whole blood |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11266337B2 (en) | 2015-09-09 | 2022-03-08 | Drawbridge Health, Inc. | Systems, methods, and devices for sample collection, stabilization and preservation |
US10638963B2 (en) * | 2017-01-10 | 2020-05-05 | Drawbridge Health, Inc. | Devices, systems, and methods for sample collection |
US10888259B2 (en) | 2017-01-10 | 2021-01-12 | Drawbridge Health, Inc. | Cartridge assemblies for storing biological samples |
US10932710B2 (en) | 2017-01-10 | 2021-03-02 | Drawbridge Health, Inc. | Carriers for storage and transport of biological samples |
US11298060B2 (en) | 2017-01-10 | 2022-04-12 | Drawbridge Health, Inc. | Devices for collecting biological samples |
US11603254B1 (en) * | 2019-10-18 | 2023-03-14 | University Of South Florida | Miniature pressure-driven pumps |
CN112014196A (en) * | 2020-08-15 | 2020-12-01 | 湖南伊鸿健康科技有限公司 | Dilution method for classifying and counting white blood cells |
Also Published As
Publication number | Publication date |
---|---|
EP2522999B1 (en) | 2014-11-19 |
JP5559096B2 (en) | 2014-07-23 |
CN102778425A (en) | 2012-11-14 |
US8927228B2 (en) | 2015-01-06 |
JP2012237605A (en) | 2012-12-06 |
US20140017719A1 (en) | 2014-01-16 |
EP2522999A1 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8927228B2 (en) | Reagent for blood cell counting and blood analysis method | |
EP1516170B1 (en) | Lysing reagent, cartridge and automatic electronic cell counter for simultaneous enumeration of different types of white blood cells | |
van Berkel et al. | Integrated systems for rapid point of care (PoC) blood cell analysis | |
CA1045960A (en) | Multi-purpose diluent for use in blood analysis by electronic instrumentation of the coulter type | |
EP2216095A1 (en) | Microfluidic device for full blood count | |
JP5122967B2 (en) | Lysis reagent for simultaneous enumeration of different types of blood cells in blood samples | |
CN102822670B (en) | Method and system for analyzing a blood sample | |
CN104698157A (en) | Agent for blood cell analyzer | |
US20020098589A1 (en) | Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells | |
US20200150021A1 (en) | Bone marrow fluid analysis method, sample analyzer, and non-transitory storage medium | |
CN102066914B (en) | Automated method and apparatus for detecting erroneous sample collection in clinical assays | |
CN104297134A (en) | Hemolytic agent and application thereof as well as classifying and counting method for white blood cells | |
EP2587262A2 (en) | Detection method of activated neutrophils and apparatus therefor | |
US20160002698A1 (en) | Isotonic Buffered Composition and Method That Enables Counting of Cells | |
CN110763776A (en) | LC-HG-AFS detection method of thioarsenate | |
JPWO2004097393A1 (en) | Filter and biosensor equipped with the filter | |
KR100644452B1 (en) | Preservative for body fluid | |
CN110057980A (en) | A kind of on-line gas analysis instrument state automatic monitoring device | |
Kausar et al. | Frequency of Causes of Spurious Platelets Count on Routine Complete Blood Count by an Automated Hematology Cell Analyser | |
EP4261524A1 (en) | Sample analyzer and platelet counting method | |
Fritsma | An overview of clinical laboratory hematology | |
Nemeth et al. | Measurement of erythrocyte deformability and methodological adaptation for small‐animal microsurgical models | |
KR20030066520A (en) | Cell Count Method For Low Cell Concentration | |
Fritsma | PART I Introduction to Hematology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HORIBA, LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MIYAMURA, KAZUHIRO;REEL/FRAME:028183/0733 Effective date: 20120420 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |